SCHEMBL7540775

SCHEMBL7540775

CCON=Cc1ccc(C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 3/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.41
GRIN2D O15399 2/20 0.41
GRIN3B O60391 2/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN2C Q14957 2/20 0.41
GRIN3A Q8TCU5 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13468571 1.00 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL13468050 0.82 NPC1 (0.47) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL17233060 0.82 SMN1; SMN2 (0.41) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL18608949 0.82 MAOA (0.45) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL13964883 0.82 MEN1 (0.52) SMN1; SMN2MAPTMEN1KMT2AGRIN2D
SCHEMBL14480176 0.82 MEN1 (0.52) SMN1; SMN2MAPTMEN1KMT2AGRIN2D
SCHEMBL6077675 0.82 CYP1A2 (0.49) SMN1; SMN2NPC1RAB9AMAPTMEN1
SCHEMBL3363731 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTKMT2AMAOB
SCHEMBL6077681 0.82 CYP1A2 (0.49) SMN1; SMN2NPC1RAB9AMAPTMEN1
SCHEMBL3363730 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTKMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0672746-B1 Oxime ethers and perfume and flavouring compositions containing them GIVAUDAN SA (CH) 2002-05-29 EP claimed
EP-0672746-A1 Oxime ethers and perfume and flavouring compositions containing them GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1995-09-20 EP claimed
US-20130012546-A1 FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2013-01-10 US disclosed
EP-0672746-A1 Oxime ethers and perfume and flavouring compositions containing them GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1995-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012546-A1 FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES HPD, HAAO, CYP8B1 SMN1; SMN2 4688/4885NPC1 3097/4885RAB9A 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.